Co-Target(s) Information
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T67619 | Target Info | |||
Target Name | RAC-alpha serine/threonine-protein kinase (AKT1) | ||||
Synonyms |
RAC-PK-alpha; RAC; Proto-oncogene c-Akt; Protein kinase B alpha; PKB alpha
Click to Show/Hide
|
||||
Target Type | Successful Target | ||||
Gene Name | AKT1 | ||||
Biochemical Class | Kinase | ||||
UniProt ID |
Co-Targets of This Target | Top | |||||
---|---|---|---|---|---|---|
Co-Target Name | Epidermal growth factor receptor (EGFR) | Successful Target | ||||
UniProt ID | EGFR_HUMAN | |||||
Gene Name | EGFR | |||||
Synonyms |
Receptor tyrosine-protein kinase erbB-1; Proto-oncogene c-ErbB-1; HER1; ERBB1; ERBB
Click to Show/Hide
|
|||||
Representative Drug(s) | CI-1033 | Drug Info | Ki = 0.11 nM | [1] | ||
Co-Target Name | Insulin receptor (INSR) | Successful Target | ||||
UniProt ID | INSR_HUMAN | |||||
Gene Name | INSR | |||||
Synonyms |
IR; CD220 antigen; CD220
Click to Show/Hide
|
|||||
Representative Drug(s) | BMS-754807 | Drug Info | IC50 = 1.7 nM | [2] | ||
Co-Target Name | Insulin-like growth factor I receptor (IGF1R) | Successful Target | ||||
UniProt ID | IGF1R_HUMAN | |||||
Gene Name | IGF1R | |||||
Synonyms |
Type 1 insulin-like growth factor receptor; Insulin-like growth factor 1 receptor; IGF-IR; IGF-I receptor; IGF-1R; IGF-1 receptor; CD221 antigen; CD221
Click to Show/Hide
|
|||||
Representative Drug(s) | BMS-754807 | Drug Info | IC50 = 1.8 nM | [2] | ||
Co-Target Name | BDNF/NT-3 growth factors receptor (TrkB) | Successful Target | ||||
UniProt ID | NTRK2_HUMAN | |||||
Gene Name | NTRK2 | |||||
Synonyms |
Tropomyosin-related kinase B; TrkB tyrosine kinase; Trk-B; TRKB; Neurotrophic tyrosine kinase receptor type 2; GP145-TrkB
Click to Show/Hide
|
|||||
Representative Drug(s) | BMS-754807 | Drug Info | IC50 = 4 nM | [2] | ||
Co-Target Name | Erbb2 tyrosine kinase receptor (HER2) | Successful Target | ||||
UniProt ID | ERBB2_HUMAN | |||||
Gene Name | ERBB2 | |||||
Synonyms |
p185erbB2; Tyrosine kinase-type cell surface receptor HER2; Receptor tyrosine-protein kinase erbB-2; Proto-oncogene c-ErbB-2; Proto-oncogene Neu; NGL; NEU; Metastatic lymph node gene 19 protein; MLN19; MLN 19; HER2; CD340
Click to Show/Hide
|
|||||
Representative Drug(s) | CI-1033 | Drug Info | IC50 = 5 nM | [3] | ||
Co-Target Name | Tropomyosin-related kinase A (TrkA) | Successful Target | ||||
UniProt ID | NTRK1_HUMAN | |||||
Gene Name | NTRK1 | |||||
Synonyms |
gp140trk; Tyrosine kinase receptor A; Tyrosine kinase receptor; Trk-A; TRKA; TRK1-transforming tyrosine kinase protein; TRK1 transforming tyrosinekinase protein; TRK; P140-TrkA; Neurotrophic tyrosine kinase receptor type 1; NGF-trk receptor type A; MTC; High affinity nerve growth factor receptor
Click to Show/Hide
|
|||||
Representative Drug(s) | BMS-754807 | Drug Info | IC50 = 7 nM | [2] | ||
Co-Target Name | Erbb4 tyrosine kinase receptor (Erbb-4) | Successful Target | ||||
UniProt ID | ERBB4_HUMAN | |||||
Gene Name | ERBB4 | |||||
Synonyms |
Tyrosine kinase-type cell surface receptor HER4; Receptor tyrosine-protein kinase erbB-4; Proto-oncogene-like protein c-ErbB-4; P180erbB4; HER4
Click to Show/Hide
|
|||||
Representative Drug(s) | CI-1033 | Drug Info | IC50 = 10 nM | [3] | ||
Co-Target Name | Protein kinase C alpha (PRKCA) | Successful Target | ||||
UniProt ID | KPCA_HUMAN | |||||
Gene Name | PRKCA | |||||
Synonyms |
Protein kinase C alpha type; PRKACA; PKCalpha; PKCA; PKC-alpha; PKC-A
Click to Show/Hide
|
|||||
Representative Drug(s) | Enzastaurin | Drug Info | IC50 = 39 nM | [4] | ||
Co-Target Name | Protein kinase C gamma (PRKCG) | Successful Target | ||||
UniProt ID | KPCG_HUMAN | |||||
Gene Name | PRKCG | |||||
Synonyms |
PRKCG; PKCG; PKC-gamma
Click to Show/Hide
|
|||||
Representative Drug(s) | Enzastaurin | Drug Info | IC50 = 83 nM | [4] | ||
Co-Target Name | Protein kinase C epsilon (PRKCE) | Successful Target | ||||
UniProt ID | KPCE_HUMAN | |||||
Gene Name | PRKCE | |||||
Synonyms |
Protein kinase C epsilon type; PKCE; PKC epsilon; NPKC-epsilon
Click to Show/Hide
|
|||||
Representative Drug(s) | Enzastaurin | Drug Info | IC50 = 110 nM | [4] | ||
Co-Target Name | Tyrosine-protein kinase BTK (ATK) | Successful Target | ||||
UniProt ID | BTK_HUMAN | |||||
Gene Name | BTK | |||||
Synonyms |
Bruton's tyrosine kinase; Bruton tyrosine kinase; BPK; B-cell progenitor kinase; B cell progenitor kinase; Agammaglobulinemia tyrosine kinase; Agammaglobulinaemia tyrosine kinase; AGMX1
Click to Show/Hide
|
|||||
Representative Drug(s) | CI-1033 | Drug Info | IC50 = 185 nM | [5] | ||
Co-Target Name | Rho-associated protein kinase 1 (ROCK1) | Successful Target | ||||
UniProt ID | ROCK1_HUMAN | |||||
Gene Name | ROCK1 | |||||
Synonyms |
Rok; Rho-associated, coiled-coil containing protein kinase 1; Rho-associated kinase 1; Rho kinase; ROCK1; ROCK; P160ROCK; P160(rock); P160 ROCK-1; Let-502 kinase
Click to Show/Hide
|
|||||
Representative Drug(s) | Capivasertib | Drug Info | IC50 = 470 nM | [6] | ||
Co-Target Name | RAC-gamma serine/threonine-protein kinase (AKT3) | Clinical trial Target | ||||
UniProt ID | AKT3_HUMAN | |||||
Gene Name | AKT3 | |||||
Synonyms |
STK-2; RAC-PK-gamma; Protein kinase B gamma; Protein kinase Akt-3; PKBG; PKB gamma
Click to Show/Hide
|
|||||
Representative Drug(s) | GSK2110183 | Drug Info | IC50 = 1.585 nM | Click to Show More | [7] | |
2 | GDC-0068 | Drug Info | IC50 = 8 nM | [9] | ||
3 | Capivasertib | Drug Info | IC50 = 8 nM | [6] | ||
Co-Target Name | ERK activator kinase 1 (MEK1) | Clinical trial Target | ||||
UniProt ID | MP2K1_HUMAN | |||||
Gene Name | MAP2K1 | |||||
Synonyms |
PRKMK1; Mitogen-activated protein kinase kinase 1; MKK1; MEK 1; MAPKK 1; MAPK/ERKkinase 1; MAPK/ERK kinase 1; MAP kinase kinase 1; Dual specificity mitogen-activated protein kinase kinase 1
Click to Show/Hide
|
|||||
Representative Drug(s) | CI-1040 | Drug Info | IC50 = 2 nM | [8] | ||
Co-Target Name | Protein kinase C beta (PRKCB) | Clinical trial Target | ||||
UniProt ID | KPCB_HUMAN | |||||
Gene Name | PRKCB | |||||
Synonyms |
Protein kinase C beta type; PRKCB1; PKCB; PKC-beta; PKC-B
Click to Show/Hide
|
|||||
Representative Drug(s) | Enzastaurin | Drug Info | IC50 = 6 nM | [4] | ||
Co-Target Name | Proto-oncogene c-RAF (c-RAF) | Clinical trial Target | ||||
UniProt ID | RAF1_HUMAN | |||||
Gene Name | RAF1 | |||||
Synonyms |
cRaf; Raf-1; RAF proto-oncogene serine/threonine-protein kinase; RAF
Click to Show/Hide
|
|||||
Representative Drug(s) | CI-1040 | Drug Info | IC50 = 12 nM | [10] | ||
Co-Target Name | Casein kinase II alpha (CSNK2A1) | Clinical trial Target | ||||
UniProt ID | CSK21_HUMAN | |||||
Gene Name | CSNK2A1 | |||||
Synonyms |
Protein kinase CK2; Casein kinase II subunit alpha; CK2A1; CK II alpha; CK II
Click to Show/Hide
|
|||||
Representative Drug(s) | CI-1040 | Drug Info | IC50 = 17 nM | [11] | ||
Co-Target Name | Rho-associated protein kinase 2 (ROCK2) | Successful Target | ||||
UniProt ID | ROCK2_HUMAN | |||||
Gene Name | ROCK2 | |||||
Synonyms |
p164 ROCK-2; Rho-associated, coiled-coil-containing protein kinase II; Rho-associated, coiled-coil-containing protein kinase 2; Rho kinase 2; ROCK-II; KIAA0619
Click to Show/Hide
|
|||||
Representative Drug(s) | Capivasertib | Drug Info | IC50 = 56 nM | [6] | ||
Co-Target Name | Casein kinase II (CSNK2) | Clinical trial Target | ||||
UniProt ID | CSK21_HUMAN; CSK22_HUMAN; CSK23_HUMAN; CSK2B_HUMAN | |||||
Gene Name | NO-GeName | |||||
Representative Drug(s) | CI-1040 | Drug Info | EC50 = 100 nM | [11] | ||
Co-Target Name | Protein kinase C delta (PRKCD) | Clinical trial Target | ||||
UniProt ID | KPCD_HUMAN | |||||
Gene Name | PRKCD | |||||
Synonyms |
nPKC-delta; Tyrosine-protein kinase PRKCD; SDK1; Protein kinase C delta type catalytic subunit; Protein kinase C delta type; PKC-delta
Click to Show/Hide
|
|||||
Representative Drug(s) | Enzastaurin | Drug Info | IC50 = 1000 nM | [12] | ||
Co-Target Name | B lymphocyte kinase (BLK) | Patented-recorded Target | ||||
UniProt ID | BLK_HUMAN | |||||
Gene Name | BLK | |||||
Synonyms |
p55-Blk; Tyrosine-protein kinase Blk
Click to Show/Hide
|
|||||
Representative Drug(s) | CI-1033 | Drug Info | IC50 = 29 nM | [5] | ||
Co-Target Name | Tyrosine-protein kinase BMX (BMX) | Patented-recorded Target | ||||
UniProt ID | BMX_HUMAN | |||||
Gene Name | BMX | |||||
Synonyms |
NTK38; Epithelial and endothelial tyrosine kinase; ETK; Cytoplasmic tyrosine-protein kinase BMX; Bone marrow tyrosine kinase gene in chromosome X protein
Click to Show/Hide
|
|||||
Representative Drug(s) | CI-1033 | Drug Info | IC50 = 62 nM | [5] | ||
Co-Target Name | RAC-beta serine/threonine-protein kinase (AKT2) | Literature-reported Target | ||||
UniProt ID | AKT2_HUMAN | |||||
Gene Name | AKT2 | |||||
Synonyms |
RAC-PK-beta; Protein kinase B beta; Protein kinase Akt-2; PKB beta
Click to Show/Hide
|
|||||
Representative Drug(s) | Capivasertib | Drug Info | IC50 = 8 nM | Click to Show More | [6] | |
2 | GSK2110183 | Drug Info | IC50 = 10 nM | [7] | ||
3 | GDC-0068 | Drug Info | IC50 = 18 nM | [9] | ||
Co-Target Name | Protein kinase G1 (PRKG1) | Literature-reported Target | ||||
UniProt ID | KGP1_HUMAN | |||||
Gene Name | PRKG1 | |||||
Synonyms |
cGMP-dependent protein kinase I; cGMP-dependent protein kinase 1; cGKI; cGK1; cGK 1; PRKGR1B; PRKGR1A; PRKG1B
Click to Show/Hide
|
|||||
Representative Drug(s) | GDC-0068 | Drug Info | IC50 = 69 nM | [9] | ||
Co-Target Name | Protein kinase C eta (PRKCH) | Co-Target | ||||
UniProt ID | KPCL_HUMAN | |||||
Gene Name | PRKCH | |||||
Synonyms |
Protein kinase C eta type; PKC-L; nPKC-eta
Click to Show/Hide
|
|||||
Representative Drug(s) | Enzastaurin | Drug Info | IC50 = 400 nM | [12] |
References | Top | ||||
---|---|---|---|---|---|
REF 1 | Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants. J Med Chem. 2016 Mar 10;59(5):2005-24. | ||||
REF 2 | Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application. J Med Chem. 2019 Feb 28;62(4):1731-1760. | ||||
REF 3 | Irreversible protein kinase inhibitors: balancing the benefits and risks. J Med Chem. 2012 Jul 26;55(14):6243-62. | ||||
REF 4 | Synthesis and anticancer activity of novel bisindolylhydroxymaleimide derivatives with potent GSK-3 kinase inhibition. Bioorg Med Chem. 2018 Aug 7;26(14):4209-24. | ||||
REF 5 | Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5916-9. | ||||
REF 6 | Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases. J Med Chem. 2013 Mar 14;56(5):2059-73. | ||||
REF 7 | US patent application no. 20110071182A1, Inhibitors of AKT Activity | ||||
REF 8 | Synthesis and evaluation of 4-anilino-6,7-dialkoxy-3-quinolinecarbonitriles as inhibitors of kinases of the Ras-MAPK signaling cascade. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3031-4. | ||||
REF 9 | Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors. J Med Chem. 2012 Sep 27;55(18):8110-27. | ||||
REF 10 | Pharmacophore identification of Raf-1 kinase inhibitors. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2346-50. | ||||
REF 11 | 2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 2. Structure-Based Optimization and Investigation of Effects Specific to the Allosteric Mode of Action. J Med Chem. 2019 Feb 28;62(4):1817-1836. | ||||
REF 12 | Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta. Bioorg Med Chem Lett. 2003 Jun 2;13(11):1857-9. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.